61,402 Shares in Exelixis, Inc. $EXEL Purchased by Strs Ohio

Key Points

• Strs Ohio has made a new investment in Exelixis, acquiring 61,402 shares valued at approximately $2.27 million.
• Exelixis reported earnings of $0.75 per share, exceeding analysts' expectations but showing a 10.8% year-over-year revenue decline.
• Institutional investors now own 85.27% of Exelixis's stock, indicating significant confidence in the company's performance among large stakeholders.

Strs Ohio purchased a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 61,402 shares of the biotechnology company's stock, valued at approximately $2,267,000.

Several other large investors have also modified their holdings of EXEL. Janus Henderson Group PLC lifted its stake in shares of Exelixis by 1.3% in the 4th quarter. Janus Henderson Group PLC now owns 124,905 shares of the biotechnology company's stock valued at $4,160,000 after purchasing an additional 1,558 shares during the last quarter. Quantinno Capital Management LP acquired a new position in shares of Exelixis in the 4th quarter valued at $559,000. Raiffeisen Bank International AG acquired a new position in Exelixis during the fourth quarter worth $100,000. State of Wyoming lifted its stake in Exelixis by 357.4% during the fourth quarter. State of Wyoming now owns 12,360 shares of the biotechnology company's stock worth $412,000 after purchasing an additional 9,658 shares in the last quarter. Finally, Teza Capital Management LLC acquired a new position in Exelixis during the fourth quarter worth $1,033,000. Institutional investors and hedge funds own 85.27% of the company's stock.

Exelixis Trading Up 3.3%

Shares of Exelixis stock traded up $1.30 on Wednesday, hitting $40.44. The stock had a trading volume of 2,663,904 shares, compared to its average volume of 2,202,123. Exelixis, Inc. has a 52-week low of $25.17 and a 52-week high of $49.62. The stock has a market cap of $10.89 billion, a price-to-earnings ratio of 19.44, a P/E/G ratio of 0.81 and a beta of 0.32. The company's 50 day moving average price is $39.71 and its 200 day moving average price is $39.66.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.12. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The business had revenue of $568.26 million during the quarter, compared to the consensus estimate of $574.36 million. During the same period in the previous year, the business earned $0.84 EPS. The business's quarterly revenue was down 10.8% on a year-over-year basis. Exelixis has set its FY 2025 guidance at EPS. Analysts predict that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on EXEL. Barclays began coverage on Exelixis in a research note on Wednesday. They set an "equal weight" rating and a $40.00 price target on the stock. Jefferies Financial Group set a $50.00 price objective on Exelixis and gave the company a "buy" rating in a research note on Tuesday, June 24th. Bank of America increased their price objective on Exelixis from $45.00 to $46.00 and gave the company a "neutral" rating in a research note on Thursday, June 5th. HC Wainwright reduced their price objective on Exelixis from $53.00 to $46.00 and set a "buy" rating on the stock in a research note on Tuesday, August 12th. Finally, Truist Financial reduced their price objective on Exelixis from $56.00 to $49.00 and set a "buy" rating on the stock in a research note on Tuesday, July 29th. Fourteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $44.42.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.